OFIX on Nasdaq
Orthofix Medical Inc.
Orthofix Medical Inc. is a global medical technology company headquartered in Lewisville.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Alphatec Holdings, Inc., iRhythm Holdings, Inc. or Inspire Medical Systems (United States), or pick any stock.
- TickerOFIX on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersLewisville, Texas1
- Business address3451 Plano Parkway, Lewisville, Tx 750562
- Filer categoryAccelerated filer2
See how the biggest companies compare on our leaderboards
Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, Orthofix delivers exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
68.8%Gross margin5
-9.9%Operating margin5
-11.2%Net margin5
2.9%Revenue growth, 20255
-20.5%Return on equity5
0.35×Debt to equity5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Global Spine brought in 84% of the revenue Orthofix Medical Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Global Spine | $631.3M | $675.3M | $687.7M |
| Global Limb Reconstruction | $115.3M | $124.2M | $134.7M |
Regions
United States brought in 83% of the revenue Orthofix Medical Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $620.8M | $672.8M | $684.1M |
| Other Countries | $65.8M | $66.4M | $76.7M |
| Italy | $20.1M | $21.0M | $22.3M |
| United Kingdom | $10.9M | $11.2M | $13.3M |
| France | $11.1M | $13.4M | $12.0M |
| Germany | $11.5M | $9.0M | $9.1M |
| Brazil | $6.5M | $5.7M | $4.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue29¢$256.3M
- Research and development8¢$65.8M
- Selling, general and admin63¢$554.3M
- Income tax0¢$1.4M
Out of $822.3M in revenue.5 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$33.3M
Out of $33.3M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net sales | $822.3M | $799.5M | $746.6M |
| Cost of sales | $256.3M | $253.6M | $260.4M |
| Gross profit | $566.0M | $545.9M | $486.3M |
| Sales, general, and administrative | $554.3M | $532.5M | $530.4M |
| Research and development | $65.8M | $73.6M | $80.2M |
| Acquisition-related amortization, impairment, and remeasurement (Note 17) | $27.3M | $24.3M | $14.8M |
| Operating loss | -$81.4M | -$84.6M | -$139.1M |
| Interest expense, net | -$17.5M | -$29.6M | -$8.6M |
| Other (expense) income, net | $8.1M | -$9.6M | -$938.0K |
| Loss before income taxes | -$90.8M | -$123.9M | -$148.7M |
| Income tax expense | -$1.4M | -$2.1M | -$2.7M |
| Net loss | -$92.2M | -$126.0M | -$151.4M |
| Basic | -$2.33 | -$3.30 | -$4.12 |
| Diluted | -$2.33 | -$3.30 | -$4.12 |
| Basic | 39.6M shares | 38.1M shares | 36.7M shares |
| Diluted | 39.6M shares | 38.1M shares | 36.7M shares |
| Unrealized loss on debt securities | -$1.3M | ||
| Currency translation adjustment | $4.9M | -$3.0M | $1.4M |
| Other comprehensive income (loss), before tax | $4.9M | -$3.0M | $83.0K |
| Other comprehensive income (loss), net of tax | $4.9M | -$3.0M | $83.0K |
| Comprehensive loss | -$87.3M | -$129.0M | -$151.3M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $82.0M | $83.2M | $33.1M | |
| Restricted cash | $3.1M | $2.5M | ||
| Accounts receivable, net of allowances of $8,308 and $7,418, respectively | $135.7M | $134.7M | ||
| Inventories | $172.3M | $189.5M | ||
| Prepaid expenses and other current assets | $23.7M | $23.4M | ||
| Total current assets | $416.8M | $433.3M | ||
| Property, plant, and equipment, net | $129.4M | $139.8M | ||
| Intangible assets, net | $72.8M | $98.8M | ||
| Goodwill | $194.9M | $194.9M | ||
| Other long-term assets | $36.7M | $26.5M | ||
| Total assets | $850.6M | $893.3M | ||
| Accounts payable | $58.4M | $48.8M | ||
| Current portion of long-term debt | $0 | $0 | ||
| Current portion of finance lease liability | $837.0K | $755.0K | ||
| Other current liabilities | $111.3M | $119.1M | ||
| Total current liabilities | $170.5M | $168.6M | ||
| Long-term debt | $157.4M | $157.0M | ||
| Long-term portion of finance lease liability | $17.1M | $17.8M | ||
| Other long-term liabilities | $55.7M | $46.7M | ||
| Total liabilities | $400.6M | $390.2M | ||
| Common shares $0.10 par value; 100,000 shares authorized; 39,834 and 38,486 issued and outstanding as of December 31,2025 and 2024, respectively | $4.0M | $3.8M | ||
| Additional paid-in capital | $813.8M | $779.7M | ||
| Accumulated deficit | -$368.3M | -$276.1M | ||
| Accumulated other comprehensive income (loss) | $618.0K | -$4.3M | ||
| Total shareholders equity | $450.0M | $503.1M | $598.7M | $336.9M |
| Total liabilities and shareholders equity | $850.6M | $893.3M | ||
| Trade accounts receivable, allowance for doubtful accounts | $8.3M | $7.4M | ||
| Common shares, par value | $0.10 | $0.10 | ||
| Common shares, authorized | 100.0M shares | 100.0M shares | ||
| Common shares, issued | 39.8M shares | 38.5M shares | ||
| Common shares, outstanding | 39.8M shares | 38.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $82.0M | $83.2M | $33.1M | |
| Restricted cash | $3.1M | $2.5M | ||
| Accounts receivable, net of allowances of $8,308 and $7,418, respectively | $135.7M | $134.7M | ||
| Inventories | $172.3M | $189.5M | ||
| Prepaid expenses and other current assets | $23.7M | $23.4M | ||
| Total current assets | $416.8M | $433.3M | ||
| Property, plant, and equipment, net | $129.4M | $139.8M | ||
| Intangible assets, net | $72.8M | $98.8M | ||
| Goodwill | $194.9M | $194.9M | ||
| Other long-term assets | $36.7M | $26.5M | ||
| Total assets | $850.6M | $893.3M | ||
| Accounts payable | $58.4M | $48.8M | ||
| Current portion of long-term debt | $0 | $0 | ||
| Current portion of finance lease liability | $837.0K | $755.0K | ||
| Other current liabilities | $111.3M | $119.1M | ||
| Total current liabilities | $170.5M | $168.6M | ||
| Long-term debt | $157.4M | $157.0M | ||
| Long-term portion of finance lease liability | $17.1M | $17.8M | ||
| Other long-term liabilities | $55.7M | $46.7M | ||
| Total liabilities | $400.6M | $390.2M | ||
| Common shares $0.10 par value; 100,000 shares authorized; 39,834 and 38,486 issued and outstanding as of December 31,2025 and 2024, respectively | $4.0M | $3.8M | ||
| Additional paid-in capital | $813.8M | $779.7M | ||
| Accumulated deficit | -$368.3M | -$276.1M | ||
| Accumulated other comprehensive income (loss) | $618.0K | -$4.3M | ||
| Total shareholders equity | $450.0M | $503.1M | $598.7M | $336.9M |
| Total liabilities and shareholders equity | $850.6M | $893.3M | ||
| Trade accounts receivable, allowance for doubtful accounts | $8.3M | $7.4M | ||
| Common shares, par value | $0.10 | $0.10 | ||
| Common shares, authorized | 100.0M shares | 100.0M shares | ||
| Common shares, issued | 39.8M shares | 38.5M shares | ||
| Common shares, outstanding | 39.8M shares | 38.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$92.2M | -$126.0M | -$151.4M |
| Depreciation, amortization, and impairment | $77.3M | $60.1M | $53.1M |
| Inventory reserve expenses | $30.8M | $26.3M | $27.6M |
| Amortization of inventory fair value step-up | $12.2M | $36.0M | |
| Amortization of operating lease assets, debt costs, and other assets | $5.9M | $15.9M | $7.5M |
| Provision for expected credit losses | $2.3M | $2.0M | $820.0K |
| Deferred income taxes | $223.0K | $1.9M | $579.0K |
| Share-based compensation expense | $28.7M | $32.5M | $35.7M |
| Loss on disposal of fixed assets | $1.1M | $2.0M | $2.3M |
| Change in valuation of investment securities | -$48.0K | $7.5M | $596.0K |
| Change in fair value of contingent consideration | -$1.1M | $6.9M | -$2.7M |
| Other | $1.8M | $3.8M | -$1.9M |
| Accounts receivable | -$1.6M | -$9.5M | -$10.4M |
| Inventories | -$10.7M | -$5.5M | -$58.1M |
| Prepaid expenses and other current assets | -$3.9M | $593.0K | $1.8M |
| Accounts payable | $2.6M | -$5.6M | $8.6M |
| Other current liabilities | -$2.3M | $9.5M | $4.1M |
| Contingent consideration milestone payment | -$1.3M | ||
| Other long-term assets and liabilities | -$4.2M | -$8.7M | $27.0K |
| Net cash provided by (used in) operating activities | $33.3M | $25.8M | -$45.8M |
| Capital expenditures | -$34.6M | -$34.9M | -$62.0M |
| Cash acquired in SeaSpine merger | $29.4M | ||
| Sale of investment securities | $7.4M | ||
| Other investing activities | $28.0K | -$100.0K | -$500.0K |
| Net cash used in investing activities | -$34.6M | -$27.6M | -$33.1M |
| Proceeds from credit facilities | $197.6M | $174.5M | |
| Repayment of borrowings from credit facilities | -$142.5M | -$79.0M | |
| Payment of debt acquired from SeaSpine merger | -$26.9M | ||
| Proceeds from issuance of common shares | $5.9M | $6.3M | $5.1M |
| Payments related to withholdings for share-based compensation | -$432.0K | -$5.3M | -$4.4M |
| Contingent consideration milestone payment | -$5.0M | -$1.0M | -$1.0M |
| Payments related to finance lease obligation | -$762.0K | -$706.0K | -$652.0K |
| Payment of debt issuance costs and other financing activities | -$531.0K | -$3.6M | -$2.4M |
| Net cash provided by (used in) financing activities | -$786.0K | $50.7M | $65.3M |
| Effect of exchange rate changes on cash and restricted cash | $1.4M | -$938.0K | $619.0K |
| Net change in cash, cash equivalents, and restricted cash | -$623.0K | $48.0M | -$12.9M |
No quarter-by-quarter statement was filed.
Corporate structure
Orthofix Medical Inc. sits at the top of its group. 11 entities, 9 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Orthofix Medical Inc.
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Orthofix Medical Inc., latest Aug 14, 2026 (9 filings since Feb 14, 2024)
- Juniper Investment Company, LLC Filed SCHEDULE 13D/A on Orthofix Medical Inc., latest May 27, 2026 (6 filings since Jan 7, 2025)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Orthofix Medical Inc., latest Mar 27, 2026 (4 filings since Feb 10, 2022)
- ENGINE CAPITAL, L.P. Filed SCHEDULE 13D/A on Orthofix Medical Inc., latest May 8, 2025 (5 filings since Nov 3, 2023)
- BlackRock Filed SCHEDULE 13G/A on Orthofix Medical Inc., latest Apr 17, 2025 (5 filings since Jan 25, 2022)
- PARADIGM CAPITAL MANAGEMENT INC/NY Filed SC 13G on Orthofix Medical Inc., latest Nov 13, 2024
- Morgan Stanley Filed SC 13G/A on Orthofix Medical Inc., latest Nov 8, 2024 (2 filings since Feb 9, 2024)
- Rubric Capital Management LP Filed SC 13G on Orthofix Medical Inc., latest Feb 12, 2024
- SEGALL BRYANT & HAMILL, LLC Filed SC 13G/A on Orthofix Medical Inc., latest Feb 9, 2024
- First Light Asset Management, LLC Filed SC 13G/A on Orthofix Medical Inc., latest Oct 30, 2023 (2 filings since Feb 14, 2023)
- Paradice Investment Management LLC Filed SC 13G/A on Orthofix Medical Inc., latest Feb 9, 2023 (2 filings since Feb 10, 2022)
- Orthofix Medical Inc. Lewisville, Texas
- 7D Surgical ULC Subsidiary · Canada
- Implantes y Sistemas Medicos, Inc. Subsidiary · Puerto Rico, United States
- IsoTis International SARL Subsidiary · Switzerland
- Orthofix AG Subsidiary · Switzerland
- Orthofix Australia Pty. Ltd. Subsidiary · Australia
- Orthofix do Brasil Ltda. Subsidiary · Brazil
- Orthofix France SAS Subsidiary · France
- Orthofix Netherlands B.V. Subsidiary · Netherlands
- Orthofix S.r.l. Subsidiary · Italy
- Orthofix Spine GmbH Subsidiary · Germany
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Orthofix Medical Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $380.1M5 Dec 31, 2025 | $352.0M5 Dec 31, 2024 | +8.0% |
| Accumulated depreciation | $250.7M5 Dec 31, 2025 | $212.2M5 Dec 31, 2024 | +18.1% |
| Property and equipment, net | $129.4M5 Dec 31, 2025 | $139.8M5 Dec 31, 2024 | −7.4% |
| Finance-lease assets | $14.4M5 Dec 31, 2025 | $15.4M5 Dec 31, 2024 | −6.1% |
| Operating-lease assets (leased space) | $22.3M5 Dec 31, 2025 | $17.2M5 Dec 31, 2024 | +29.2% |
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $194.9M5 Dec 31, 2025 | $194.9M5 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $72.8M5 Dec 31, 2025 | $98.8M5 Dec 31, 2024 | −26.4% |
| Indefinite-lived intangibles (excluding goodwill) | $1.0M5 Dec 31, 2025 | $4.1M9 Dec 31, 2024 | −75.1% |
| Accumulated amortization | $145.7M5 Dec 31, 2025 | $105.6M5 Dec 31, 2024 | +38.0% |
| Finite-lived intangibles, net | $71.7M5 Dec 31, 2025 | $94.7M9 Dec 31, 2024 | −24.2% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $172.3M5 Dec 31, 2025 | $189.5M5 Dec 31, 2024 | −9.0% |
| Raw materials | $22.9M5 Dec 31, 2025 | $27.2M5 Dec 31, 2024 | −15.9% |
| Work in process | $63.3M5 Dec 31, 2025 | $56.9M5 Dec 31, 2024 | +11.1% |
| Finished goods | $86.2M5 Dec 31, 2025 | $105.4M5 Dec 31, 2024 | −18.2% |
Properties, in its own words
We lease or own real property to support our business. The following lists those properties that we believe are material to our business. We believe that our facilities meet our current needs and that we will be able to renew any such leases when needed on acceptable terms or find alternative facilities.
Facility · Location · Approx.SquareFeet · Ownership
The rest of Item 2
Manufacturing, warehousing, distribution, research and development, location of a cadaveric training laboratory, and administrative facility for corporate functions and all reporting segments · Lewisville, TX · 140,000 · Leased
Design, development, marketing, and inspection for biologics and spinal implant products, distribution of certain Spinal Implant products, location of a cadaveric training laboratory, and administrative facility · Carlsbad, CA · 82,000 · Leased
Manufacturing and distribution for certain Biologics products · Irvine, CA · 70,000 · Leased
Manufacturing, warehousing, distribution, research and development, and administrative facility for Motion Preservation · Sunnyvale, CA · 25,000 · Leased
Design of Spinal Implants and location of a cadaveric training laboratory · Wayne, PA · 3,700 · Leased
Design, development, and marketing for Enabling Technologies products · Toronto, Canada · 9,200 · Leased
Research and development, component manufacturing, quality control and training facility for Limb Reconstruction products and sales management, distribution and administrative facility for Italy · Verona, Italy · 38,000 · Owned
International distribution center for Limb Reconstruction products · Verona, Italy · 18,000 · Leased
Mechanical workshop for Limb Reconstruction products · Verona, Italy · 9,000 · Leased
Sales management, distribution and administrative facility for United Kingdom · Maidenhead, England · 5,600 · Leased
Sales management, distribution and administrative facility for Brazil · São Paulo, Brazil · 26,300 · Leased
Sales management, distribution and administrative facility for France · Arcueil, France · 8,500 · Leased
Sales management, distribution and administrative facility for Germany · Munich, Germany · 2,300 · Leased
Our manufacturing facilities are registered with the FDA. Our facilities are subject to FDA inspection to ensure compliance with its QSRs. For further information regarding the status of FDA inspections, see Item 1, "Business", under the subheading "Government Regulation."
Item 2 of the 10-K filed Feb 24, 2026.4
Leadership
Who has led Orthofix Medical Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
- Charles Federico2006
- Gary Henley2006
- Alan Milinazzo2006–2011
- Bradley R. Mason2006–2009
- Oliver Burckhardt2006–2008
- Matthew Lyons2007
- Scott Dodson2007
- Luigi Ferrari2008–2012
- Kevin Unger2009
- Bryan McMillan2011–2012
- Michael Finegan2012
- Robert S. Vaters2012–2013
- Bradley Niemann V.2016–2019
- Raymond Fujikawa2016–2018
- Robert Allen Goodwin Ii.2016–2018
- Davide Bianchi2017–2019
- Jon Carl Serbousek2019
- Kevin J. Kenny2019–2024
- Paul Gonsalves2020–2022
- Kimberley A. Elting2022–2024
- Keith Valentine2023
- Massimo Calafiore2024
- Max Reinhardt2024
- Patrick Fisher2024–now
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerMassimo Calafiore Jan 10, 2024 to now13
- Chief executive officerKeith Valentine Jan 9, 2023 to Mar 2, 202314
- Chief executive officerCatherine M. Burzik Oct 17, 2023 to Oct 17, 202315
- Chief executive officerJon Carl Serbousek Nov 5, 2019 to Nov 3, 202216
- Chief executive officerRobert S. Vaters Feb 16, 2012 to Feb 27, 201317
- Chief executive officerCharles Federico Mar 7, 2006 to Mar 10, 200618
- Chief executive officerAlan Milinazzo Apr 12, 2006 to Feb 17, 201119
- ChairJon Carl Serbousek Jan 9, 2023 to Apr 5, 202320
- ChairJames Gero Aug 18, 2006 to Jul 1, 200921
- PresidentMassimo Calafiore Jan 10, 2024 to Jun 12, 202413
- PresidentMax Reinhardt Jun 12, 2024 to Aug 19, 202422
- PresidentPatrick Fisher Aug 19, 2024 to now23
- PresidentKeith Valentine Jan 9, 2023 to Mar 2, 202314
- PresidentKimberley A. Elting Apr 13, 2022 to Jun 12, 202424
- PresidentPaul Gonsalves Sep 14, 2020 to Apr 5, 202225
- PresidentJon Carl Serbousek Aug 5, 2019 to Aug 5, 201926
- PresidentKevin J. Kenny Dec 5, 2019 to Jan 10, 202427
- PresidentDavide Bianchi Jul 10, 2017 to Jul 10, 201928
- PresidentBradley Niemann V. Mar 21, 2016 to Jul 15, 201929
- PresidentRaymond Fujikawa Mar 21, 2016 to Jun 21, 201830
- PresidentRobert Allen Goodwin Ii. Mar 21, 2016 to Apr 3, 201831
- PresidentMichael Finegan Feb 16, 2012 to Aug 17, 201232
- PresidentRobert S. Vaters Feb 16, 2012 to Feb 27, 201317
- PresidentBryan McMillan Oct 4, 2011 to Aug 1, 201233
- PresidentKevin Unger Dec 9, 2009 to Dec 9, 200934
- PresidentLuigi Ferrari Apr 22, 2008 to Aug 21, 201235
- PresidentMatthew Lyons Jan 17, 2007 to Jan 17, 200736
- PresidentScott Dodson Jun 6, 2007 to Jul 3, 200737
- PresidentCharles Federico Mar 7, 2006 to Mar 10, 200618
- PresidentGary Henley Mar 20, 2006 to Mar 20, 200638
- PresidentAlan Milinazzo Apr 12, 2006 to Feb 17, 201119
- PresidentBradley R. Mason Jul 6, 2006 to Jul 29, 200939
- PresidentOliver Burckhardt Nov 21, 2006 to Jul 1, 200840
- Chief financial officerJulie Andrews Jan 17, 2024 to now41
- Chief financial officerJohn J. Bostjancic Jan 9, 2023 to Mar 2, 202342
- Chief financial officerGeoffrey C. Gillespie Sep 18, 2023 to Jan 9, 202443
- Chief financial officerDavid E. Ziegler Apr 28, 2014 to Apr 28, 201444
- Chief financial officerMark A. Heggestad May 14, 2014 to Jul 2, 201445
- Chief financial officerRice Doug Oct 6, 2014 to Apr 13, 202246
- Chief financial officerEmily Buxton Nov 19, 2012 to Sep 27, 201347
- Chief financial officerBrian McCollum Jan 14, 2011 to Aug 1, 201248
- Chief financial officerRobert S. Vaters Sep 9, 2008 to Jul 29, 200949
- Chief financial officerTimothy M. Adams Nov 21, 2007 to May 1, 200850
- Chief financial officerThomas M. Hein Jul 6, 2006 to Apr 15, 200851
- Chief operating officerRobert S. Vaters Feb 17, 2011 to Jun 16, 201152
- Chief operating officerAlan Milinazzo May 12, 2006 to May 12, 200653
Board members and other officers (47)
- Pres, Global Ops & QualAviva McPherron May 9, 2025 to now54
- CAOGeoffrey C. Gillespie Mar 19, 2024 to now55
- CP&BOLucas Vitale Jun 26, 2024 to now56
- Chief Accounting OfficerRice Doug Sep 8, 2014 to Sep 8, 201457
- Pres, Int'l Extremity FixationDavide Bianchi Sep 27, 2013 to Jul 6, 201658
- SVP - Worldwide OperationsVicente Trelles Apr 4, 2011 to Aug 1, 201259
- Vice President of FinanceThomas M. Hein Feb 11, 2009 to Feb 11, 200960
- VP, Corporate DevelopmentMichael Finegan Feb 28, 2007 to Jul 6, 202061
- Board memberVickie L. Capps Mar 13, 2025 to now62
- Board memberMassimo Calafiore Jan 23, 2024 to now63
- Board memberJohn B. Henneman Iii. Jan 9, 2023 to now64
- Board memberKeith Valentine Jan 9, 2023 to Mar 2, 202314
- Board memberShweta Maniar Jan 9, 2023 to now65
- Board memberStuart Essig Jan 9, 2023 to Feb 9, 202366
- Board memberAlan Lee Bazaar Dec 14, 2023 to now67
- Board memberCharles R. Kummeth Dec 20, 2023 to now68
- Board memberMichael Finegan Dec 20, 2023 to now69
- Board memberCatherine M. Burzik Jun 23, 2021 to Apr 9, 202470
- Board memberWayne Burris Sep 29, 2021 to now71
- Board memberThomas A. West Dec 15, 2021 to Jan 11, 202372
- Board memberJason Hannon Jun 10, 2020 to now73
- Board memberJon Carl Serbousek Nov 5, 2019 to Nov 3, 202216
- Board memberJohn Sicard Mar 13, 2018 to Jun 8, 202274
- Board memberMichael E. Paolucci Mar 17, 2016 to now75
- Board memberAlexis Lukianov V. Dec 15, 2016 to Jun 23, 202176
- Board memberLilly Marks Jun 25, 2015 to Jan 11, 202377
- Board memberRonald A. Matricaria Mar 31, 2014 to Jun 10, 202078
- Board memberJames F. Hinrichs Apr 28, 2014 to Sep 14, 202379
- Board memberLuke T. Faulstick Sep 22, 2014 to Nov 6, 201880
- Board memberKathleen T. Regan Nov 20, 2013 to Jul 8, 201481
- Board memberRandy H. Thurman Nov 21, 2013 to Nov 21, 201382
- Board memberAnthony Francis Martin Dec 6, 2013 to Jul 6, 201683
- Board memberDavey Scoon Aug 17, 2011 to May 22, 201584
- Board memberJames Gero Aug 17, 2011 to Sep 27, 201385
- Board memberMichael Mainelli Aug 21, 2009 to May 15, 201386
- Board memberThomas J. Kester May 16, 2007 to Dec 17, 201087
- Board memberGuy J. Jordan Jul 2, 2007 to Jul 6, 201688
- Board memberKenneth R. Weisshaar Jul 2, 2007 to Mar 3, 201489
- Board memberPeter J. Hewett Jul 2, 2007 to Jun 23, 200890
- Board memberWartburg Walter P. Von Jul 2, 2007 to Sep 27, 201391
- Board memberCharles Federico Mar 7, 2006 to Jul 1, 200918
- Board memberCooper Robert Gaines Mar 9, 2006 to Jun 15, 200792
- General counselJorge Andres Cedron Apr 17, 2024 to now93
- General counselPatrick L. Keran Jan 9, 2023 to Mar 2, 202394
- General counselPuja Leekha Sep 18, 2023 to Oct 17, 202395
- General counselKimberley A. Elting Sep 28, 2016 to Apr 5, 202296
- General counselRaymond C. Kolls Jul 6, 2006 to Jul 28, 200997
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- 7D Surgical ULC Canada3
- Implantes y Sistemas Medicos, Inc. Puerto Rico3
- IsoTis International SARL Switzerland3
- Orthofix AG Switzerland3
- Orthofix Australia Pty. Ltd. Australia3
- Orthofix France SAS France3
- Orthofix GmbH Germany3
- Orthofix Limited UK3
- Orthofix Netherlands B.V. Netherlands3
- Orthofix S.r.l. Italy3
- Orthofix Spine GmbH Germany3
- Orthofix do Brasil Ltda. Brazil3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- ORTHOFIX INTERNATIONAL N VSep 3, 1998 to Aug 1, 20182
Timeline
- Aug 5, 20268-K Results of operations; Regulation FD disclosure98
- Jul 2, 20268-K Regulation FD disclosure99
- Jun 11, 20268-K Executive or director change; Shareholder vote100
- May 21, 20268-K Regulation FD disclosure101
- May 5, 20268-K Results of operations; Regulation FD disclosure102
- Apr 9, 20268-K Results of operations; Executive or director change103
- Feb 24, 20268-K Results of operations; Regulation FD disclosure104
- Nov 4, 20258-K Results of operations; Regulation FD disclosure105
- Aug 5, 20258-K Results of operations; Regulation FD disclosure106
- Jun 20, 20258-K Shareholder vote107
- May 6, 20258-K Results of operations; Regulation FD disclosure108
- Apr 7, 20258-K Entered a material agreement; Ended a material agreement109
- Jan 10, 2024New chief executive Massimo Calafiore becomes CEO13
- Oct 17, 2023New chief executive Catherine M. Burzik becomes CEO15
- Jan 9, 2023New chief executive Keith Valentine becomes CEO14
- Nov 5, 2019New chief executive Jon Carl Serbousek becomes CEO16
- Feb 16, 2012New chief executive Robert S. Vaters becomes CEO17
- Apr 12, 2006New chief executive Alan Milinazzo becomes CEO19
- Mar 7, 2006New chief executive Charles Federico becomes CEO18
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.57) a share, on Nov 4, 2025.110
When it reported results
- Aug 5, 2026Reported quarterly or annual results98
- May 5, 2026Reported quarterly or annual results102
- Apr 9, 2026Reported quarterly or annual results103
- Feb 24, 2026Reported quarterly or annual results104
- Nov 4, 2025Reported quarterly or annual results105
- Aug 5, 2025Reported quarterly or annual results106
- May 6, 2025Reported quarterly or annual results108
- Feb 25, 2025Reported quarterly or annual results111
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
401 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 59 major events, 217 insider forms, 38 large holders, 67 other. The latest 20:
- Oct 5, 20264 EDGAR
- Sep 23, 20264/A PRIMARY DOCUMENT EDGAR
- Sep 22, 20264 PRIMARY DOCUMENT EDGAR
- Sep 3, 20264 EDGAR
- Sep 1, 2026144 EDGAR
- Aug 20, 20264 EDGAR
- Aug 18, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 5, 2026S-8 EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 2, 20268-K EDGAR
- Jun 22, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
The 401 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
71 open-market trades by officers, directors and large owners since October 2021: 24 buys and 47 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Bartholdson John A.10% owner | Buy | 190,000 | $8.86 | $1.7M | Form 4 |
| Sep 21, 2026 | Juniper Investment Company, LLC10% owner | Sale | 190,000 | $8.86 | $1.7M | Form 4 |
| Sep 18, 2026 | Bartholdson John A.10% owner | Buy | 120,000 | $8.74 | $1.0M | Form 4 |
| Sep 18, 2026 | Juniper Investment Company, LLC10% owner | Sale | 120,000 | $8.74 | $1.0M | Form 4 |
| Sep 1, 2026 | Fisher PatrickPresident, Global Limb Recon | Sale | 150 | $9.39 | $1.4K | Form 4 |
| Aug 18, 2026 | Fisher PatrickPresident, Global Limb Recon | Sale | 1,295 | $10.09 | $13.1K | Form 4 |
| Aug 17, 2026 | MICHAS ALEXIS P10% owner | Sale | 20,000 | $10.01 | $200.2K | Form 4 |
| Aug 14, 2026 | MICHAS ALEXIS P10% owner | Sale | 19,500 | $10.38 | $202.4K | Form 4 |
| Jun 18, 2026 | McPherron AvivaPres, Global Ops & Qual | Sale | 3,670 | $9.38 | $34.4K | Form 4 |
| May 22, 2026 | Juniper Investment Company, LLC10% owner | Sale | 242,000 | $10.70 | $2.6M | Form 4 |
| May 7, 2026 | HENNEMAN JOHN B IIIDirector | Buy | 5,000 | $12.26 | $61.3K | Form 4 |
| May 7, 2026 | Engine Jet Capital, L.P.10% owner | Buy | 30,000 | $12.18 | $365.5K | Form 4 |
| May 6, 2026 | Engine Jet Capital, L.P.10% owner | Buy | 41,946 | $12.23 | $513.0K | Form 4 |
| May 5, 2026 | Engine Jet Capital, L.P.10% owner | Buy | 112,950 | $11.99 | $1.4M | Form 4 |
| Apr 16, 2026 | Cedron Jorge AndresCLO | Sale | 3,743 | $12.82 | $48.0K | Form 4 |
| Mar 17, 2026 | Vitale LucasCP&BOO | Sale | 4,269 | $11.92 | $50.9K | Form 4 |
| Mar 10, 2026 | CAPPS VICKIE LDirector | Buy | 2,500 | $12.45 | $31.1K | Form 4 |
| Mar 9, 2026 | CAPPS VICKIE LDirector | Buy | 2,500 | $12.48 | $31.2K | Form 4 |
| Mar 5, 2026 | Andrews JulieCFO | Sale | 2,363 | $12.55 | $29.7K | Form 4 |
| Mar 5, 2026 | Vitale LucasCP&BOO | Sale | 1,141 | $12.55 | $14.3K | Form 4 |
All 71 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 9 filings Feb 14, 2024 to Aug 14, 2026112
- Juniper Investment Company, LLCSCHEDULE 13D/A, 6 filings Jan 7, 2025 to May 27, 2026113
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 2026114
- ENGINE CAPITAL, L.P.SCHEDULE 13D/A, 5 filings Nov 3, 2023 to May 8, 2025115
- BlackRockSCHEDULE 13G/A, 5 filings Jan 25, 2022 to Apr 17, 2025116
- PARADIGM CAPITAL MANAGEMENT INC/NYSC 13G, 1 filing Nov 13, 2024117
- Morgan StanleySC 13G/A, 2 filings Feb 9, 2024 to Nov 8, 2024118
- Rubric Capital Management LPSC 13G, 1 filing Feb 12, 2024119
- SEGALL BRYANT & HAMILL, LLCSC 13G/A, 1 filing Feb 9, 2024120
- First Light Asset Management, LLCSC 13G/A, 2 filings Feb 14, 2023 to Oct 30, 2023121
- Paradice Investment Management LLCSC 13G/A, 2 filings Feb 10, 2022 to Feb 9, 2023122
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Massimo Calafiore - President and | $848.3K | $7.3M123 | |
| 2025 | Julie Andrews - Chief Financial Officer | $488.4K | $3.0M123 | |
| 2025 | J. Andrés Cedrón - Chief Legal Officer | $483.3K | $2.1M123 | |
| 2025 | Aviva McPherron - PresidentGlobal Operations and Quality | $447.3K | $1.8M123 | |
| 2025 | Patrick Fisher - PresidentGlobal Biologics and Limb Reconstruction | $462.7K | $1.8M123 | |
| 2024 | Chief Executive Officer | $793.3K | $10.6M123 | |
| 2024 | Julie Andrews - Chief Financial Officer | $447.6K | $3.2M123 | |
| 2024 | J. Andrés Cedrón - Chief Legal Officer | $325.4K | $2.4M123 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Orthofix Medical Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGAROrthofix Medical Inc.1
- CIK0000884624
- Employer ID (EIN)98-13407674
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 231
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address3451 Plano Parkway, Lewisville, TX 750561
- Phone214-937-20001
- Shares outstanding40,732,608 as of Jul 31, 202611
- Public float$440.2M as of Jun 30, 20254
- AuditorErnst & Young LLP, Dallas, Texas PCAOB ID 42; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceJan 12, 19981
- Filings1,745 in all: 4 (756), 8-K (330), SC 13G/A (98), 3 (90), 10-Q (71), S-8 (37), SC 13G (35), DEFA14A (32)1
All 49 form types
4/A (25), 10-K (24), DEF 14A (24), UPLOAD (23), 425 (19), CORRESP (17), DFAN14A (16), SD (13), PRE 14A (12), 8-K/A (10), 3/A (9), SCHEDULE 13G/A (9), 10-K/A (8), S-8 POS (7), SCHEDULE 13D/A (7), 144 (6), CT ORDER (6), 20-F (5), 5 (4), 6-K (4), DEFC14A (4), DEFR14A (4), NT 10-Q (4), PREC14A (4), EFFECT (3), PRER14A (3), PRRN14A (3), SC 13D/A (3), 10-Q/A (2), 424B3 (2), DFRN14A (2), NT 10-K (2), S-4 (2), S-4/A (2), SC 13D (2), ARS (1), NTN 10Q (1), POS AM (1), PREC14C (1), S-3ASR (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Feb 24, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 29, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.10 par value | OFIX | Nasdaq Global Select Market |
From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Orthofix Medical Inc. names in Item 1A of its 10-K filed Feb 24, 2026: 52 risks under these headings, as written.4
- Risks Related to our Business and Industry
- We continue to integrate legacy businesses that operate in different market segments, and we may not be able to achieve all of our intended synergies between such legacy businesses.
- Our business may be adversely affected if consolidation in the healthcare industry leads to demand for price concessions or if a GPO or similar entity excludes us from being a supplier.
- The industry in which we operate is highly competitive. New developments by others could make our products or technologies non-competitive or obsolete.
- The COVID-19 pandemic and related supply chain and raw material disruptions previously had material adverse impacts to our global operations and financial condition. Future pandemics, wars and armed conflicts, terrorist attacks, and other such global events could similarly have a material impact on our global operations and the operations of our supply chain, which could adversely impact our business results and financial condition.
- Our ability to market products successfully depends, in part, upon the acceptance of the products not only by consumers, but also by independent third parties.
- Clinical studies are expensive and subject to extensive regulation and their results may not support our product candidate claims or may result in the discovery of adverse effects.
- If the third parties on which we rely to conduct our clinical studies and to assist us with pre-clinical development do not perform as contractually required or expected, we may not obtain regulatory clearance, approval, or a CE Certificate of Conformity for our products or be able to successfully commercialize our products.
- Our allograft and cellular bone allografts could expose us to certain risks that could disrupt our business.
- Unfavorable media reports or other negative publicity concerning both alleged improper methods of tissue recovery from donors and disease transmission from donated tissue could limit widespread acceptance of some of our products.
- We may not be able to successfully introduce new products to the market and market opportunities that we expect to develop for our products may not be as large as we expect.
- There is no guarantee that the FDA will grant 510(k) clearance or premarket approval, or that equivalent foreign regulatory authorities will grant the foreign equivalent, of our future products, and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.
The other 41 risks
- Growing our business requires that we properly educate and train physicians regarding the distinctive characteristics, benefits, safety, clinical efficacy, and cost-effectiveness of our products.
- Sales of, or the price at which we sell, our products may be adversely affected unless the safety and efficacy of our products, alone and relative to competing products, is demonstrated in clinical studies.
- We may be adversely affected by any disruption in our information technology systems, which could adversely affect our cash flows, operating results, and financial condition.
- We may be adversely affected by a failure or compromise from a cyber-attack, data breach or ransomware attack, which could have an adverse effect on our business.
- The physical effects of climate change or legal, regulatory, or market measures intended to address climate change could adversely affect our operations and operating results.
- If any of our manufacturing, development, or research facilities are damaged and/or if our manufacturing processes are interrupted, we could experience supply disruptions and/or lost revenues and our business could be seriously harmed including as the result of natural disasters and other catastrophic events outside our control.
- We depend on third-party manufacturers for many of our products.
- We depend on a limited number of third-party suppliers for processing activities, components and raw materials and losing any of these suppliers, or their inability to provide us with an adequate supply of materials that meet our quality and other requirements, could harm our business.
- If we are unable to maintain and expand our network of independent sales representatives and distributors, we may not maintain or grow our revenue.
- In order to compete, we must attract, retain, and motivate executives and key employees, and our failure to do so could have an adverse effect on our results of operations.
- Risks Related to our Legal and Regulatory Environment
- If we fail to maintain an effective system of internal controls or discover material weaknesses in our internal control over financial reporting, we may not be able to report our financial results accurately or detect fraud, which could harm our business and the trading price of our common stock.
- We are subject to the FCPA and other similar anti-bribery laws, and any violations of such laws could subject us to adverse consequences.
- We are subject to various healthcare fraud, abuse, and anti-self-referral laws, and could face substantial penalties if we are determined not to have fully complied with such laws.
- We continue to be affected by U.S. healthcare reform initiatives.
- We are subject to differing customs and import/export rules in several jurisdictions in which we operate.
- The sales and marketing practices of our industry have been the subject of increased scrutiny from federal and state government agencies.
- Reimbursement policies of third parties, cost containment measures, and healthcare reform could adversely affect the demand for our products and limit our ability to sell our products.
- We and certain of our suppliers may be subject to extensive government regulation that increases our costs and could limit our ability to market or sell our products.
- Prohibitions on promotion of "off-label" uses of medical devices might affect the way we market our products and compete in the marketplace.
- An FDA panel recommended that bone growth stimulator devices be reclassified by the FDA from Class III to Class II devices, which could increase future competition for us in this product category and negatively affect our future sales of such products.
- We are subject to requirements relating to hazardous materials which may impose significant compliance or other costs on us.
- Risks Related to our Intellectual Property
- We depend on our ability to protect our intellectual property and proprietary rights, but we may not be able to maintain the confidentiality of these assets or assure their protection.
- Third parties may claim that we infringe on their proprietary rights and may prevent us from manufacturing and selling certain of our products.
- If we seek to protect or enforce our intellectual property rights through litigation or other proceedings, it could require us to spend significant time and money, the results of which are uncertain.
- We may be subject to claims that we, our employees, or our independent sales agents or stocking distributors have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
- Risks Related to Litigation and Product Liability Matters
- We may be subject to product and other liability claims that may not be covered by insurance and could require us to pay substantial sums.
- Ongoing litigation and arbitration matters could negatively affect our business operations.
- Risks Related to Potential Acquisitions, Investments, and Divestitures
- Our efforts to identify, pursue, and implement new business opportunities (including acquisitions) may be unsuccessful and may have an adverse effect on our business.
- We may incur significant costs or retain liabilities associated with disposition activity.
- Risks Related to Our Financial Results and Financing Needs
- Our quarterly operating results may fluctuate.
- We face risks related to foreign currency exchange rates.
- Our global operations may expose us to tax risks.
- Our goodwill, intangible assets, and fixed assets are subject to potential impairment; we have recorded significant goodwill impairment charges in the past and may be required to record additional charges to future earnings if our remaining goodwill or intangible assets become impaired.
- We maintain a $275.0 million credit facility secured by a pledge of substantially all of our property.
- We may need additional financing in the future to meet our capital needs or to make opportunistic acquisitions, and such financing may not be available on favorable terms, if at all.
- We must maintain high levels of inventory, which could consume a significant amount of our resources and reduce our cash flows.
- We hold our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts that could be adversely affected if the financial institutions holding such funds fail.
- General Risks
- Our stock price has fluctuated and may continue to fluctuate, which may make future prices of our stock difficult to predict.
- We expend substantial resources to comply with laws and regulations relating to public companies, and any failure to maintain compliance could subject us to regulatory scrutiny and cause investors to lose confidence in our company, which could harm our business and have a material adverse effect on our stock price.
- Environmental, social, and corporate governance ("ESG") regulations, policies and provisions may make our supply chain more complex and may adversely affect our relationships with customers.
- Our business could be negatively impacted by corporate citizenship and ESG matters and/or our reporting of such matters.
Legal proceedings
For a description of material pending legal proceedings, refer to Note 13 of the Notes to the Consolidated Financial Statements in Item 8 of this Annual Report.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARJon Carl Serbousek, Chair
- 21SEC EDGARJames Gero, Chair
- 22SEC EDGARMax Reinhardt, President
- 23SEC EDGARPatrick Fisher, President
- 24SEC EDGARKimberley A. Elting, President
- 25SEC EDGARPaul Gonsalves, President
- 26SEC EDGARJon Carl Serbousek, President
- 27SEC EDGARKevin J. Kenny, President
- 28SEC EDGARDavide Bianchi, President
- 29SEC EDGARBradley Niemann V., President
- 30SEC EDGARRaymond Fujikawa, President
- 31SEC EDGARRobert Allen Goodwin Ii., President
- 32SEC EDGARMichael Finegan, President
- 33SEC EDGARBryan McMillan, President
- 34SEC EDGARKevin Unger, President
- 35SEC EDGARLuigi Ferrari, President
- 36SEC EDGARMatthew Lyons, President
- 37SEC EDGARScott Dodson, President
- 38SEC EDGARGary Henley, President
- 39SEC EDGARBradley R. Mason, President
- 40SEC EDGAROliver Burckhardt, President
- 41
- 42
- 43
- 44
- 45
- 46SEC EDGARRice Doug, Chief financial officer
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55SEC EDGARGeoffrey C. Gillespie, CAO
- 56SEC EDGARLucas Vitale, CP&BO
- 57SEC EDGARRice Doug, Chief Accounting Officer
- 58
- 59
- 60
- 61
- 62SEC EDGARVickie L. Capps, Board member
- 63SEC EDGARMassimo Calafiore, Board member
- 64SEC EDGARJohn B. Henneman Iii., Board member
- 65SEC EDGARShweta Maniar, Board member
- 66SEC EDGARStuart Essig, Board member
- 67SEC EDGARAlan Lee Bazaar, Board member
- 68SEC EDGARCharles R. Kummeth, Board member
- 69SEC EDGARMichael Finegan, Board member
- 70SEC EDGARCatherine M. Burzik, Board member
- 71SEC EDGARWayne Burris, Board member
- 72SEC EDGARThomas A. West, Board member
- 73SEC EDGARJason Hannon, Board member
- 74SEC EDGARJohn Sicard, Board member
- 75SEC EDGARMichael E. Paolucci, Board member
- 76SEC EDGARAlexis Lukianov V., Board member
- 77SEC EDGARLilly Marks, Board member
- 78SEC EDGARRonald A. Matricaria, Board member
- 79SEC EDGARJames F. Hinrichs, Board member
- 80SEC EDGARLuke T. Faulstick, Board member
- 81SEC EDGARKathleen T. Regan, Board member
- 82SEC EDGARRandy H. Thurman, Board member
- 83SEC EDGARAnthony Francis Martin, Board member
- 84SEC EDGARDavey Scoon, Board member
- 85SEC EDGARJames Gero, Board member
- 86SEC EDGARMichael Mainelli, Board member
- 87SEC EDGARThomas J. Kester, Board member
- 88SEC EDGARGuy J. Jordan, Board member
- 89SEC EDGARKenneth R. Weisshaar, Board member
- 90SEC EDGARPeter J. Hewett, Board member
- 91SEC EDGARWartburg Walter P. Von, Board member
- 92SEC EDGARCooper Robert Gaines, Board member
- 93SEC EDGARJorge Andres Cedron, General counsel
- 94SEC EDGARPatrick L. Keran, General counsel
- 95SEC EDGARPuja Leekha, General counsel
- 96SEC EDGARKimberley A. Elting, General counsel
- 97SEC EDGARRaymond C. Kolls, General counsel
- 98
- 99SEC EDGARRegulation FD disclosure
- 100
- 101SEC EDGARRegulation FD disclosure
- 102
- 103
- 104
- 105
- 106
- 107SEC EDGARShareholder vote
- 108
- 109
- 110NasdaqNasdaq calendar
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123